MK0518 in the Treatment of HIV-Infected Patients Switched From a Protease Inhibitor Regimen

This study has been terminated.

( primary efficacy analysis at Week 24 failed to demonstrate non-inferiority of raltegravir versus lopinavir (+) ritonavir )

Study NCT00443703 Information provided by Merck

First Received: March 2, 2007 Last Updated: September 30, 2009 History of Changes

No Study Results Posted for this Study

Study Status:	This study has been terminated.
Study Completion Date:	May 2009
Primary Completion Date:	April 2009 (Final data collection date for primary outcome measure)